Dr. Mark Jaffe, M.D.
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 258
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
FL license ME68879
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Regional Hospital Hollywood, FL
- Memorial Hospital West Pembroke Pines, FL
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 258
- Services billed
- 32,503
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 4,080 | 41 |
| Established patient office or other outpatient visit, 30-39 minutes | 302 | 150 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 107 | 46 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 88 | 14 |
| New patient office or other outpatient visit, 45-59 minutes | 68 | 68 |
| Injection, dexamethasone sodium phosphate, 1 mg | 56 | 31 |
| Injection, methylprednisolone acetate, 40 mg | 51 | 27 |
| Aspiration and/or injection of fluid from large joint | 48 | 25 |
| X-ray of wrist, 2 views | 40 | 20 |
| X-ray of hand, 2 views | 40 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Hollywood, FL | 214 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Hollywood, FL | 176 |
| Tramadol Hcl Other prescribers in Hollywood, FL | 134 |
| Methotrexate (methotrexate sodium) Other prescribers in Hollywood, FL | 90 |
| Alprazolam Other prescribers in Hollywood, FL | 84 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Hollywood, FL | 81 |
| Hydroxychloroquine Sulfate Other prescribers in Hollywood, FL | 70 |
| Gabapentin Other prescribers in Hollywood, FL | 49 |
| Duloxetine Hcl Other prescribers in Hollywood, FL | 46 |
| Allopurinol Other prescribers in Hollywood, FL | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 80 payments worth $1,252 in total to this clinician.
| Amgen Inc. | $589 |
|---|---|
| Janssen Biotech, Inc. | $213 |
| AbbVie Inc. | $210 |
| Mallinckrodt Hospital Products Inc. | $66.27 |
| E.r. Squibb & Sons, L.l.c. | $63.76 |
| UCB, Inc. | $39.83 |
| Novartis Pharmaceuticals Corporation | $26.00 |
| Pfizer Inc. | $23.21 |
| Food and Beverage | $1,252 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 8 companies. The companies reported $382,214 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1)
E.r. Squibb & Sons, L.l.c. - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
AbbVie Inc. · Active, not recruiting · NCT05843643 - A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With S…
Novartis Pharmaceuticals Corporation - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
AbbVie Inc. · Completed · NCT05814627 - A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals Corporation - A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic…
Takeda Pharmaceuticals U.S.A., Inc. - A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome
Novartis Pharmaceuticals Corporation - A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
Otsuka Pharmaceutical Development & Commercialization, Inc. · Active, not recruiting · NCT06928142 - A multicentre randomized, double-blind, placebo-controlled, dose-findi
GlaxoSmithKline, LLC. - A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.